What is Dulaglutide?
Dulaglutide is a GLP-1 receptor agonist developed for glycaemic management in type 2 diabetes. It is not simply a generic weight-loss product, and its approved use should be distinguished from other medicines in the class.
Approved-use context
Dulaglutide is authorised for type 2 diabetes in specified patients, alongside diet and exercise. Exact indications, age ranges and combinations with other medicines vary by regulator and current product information.
How it works
It activates the GLP-1 receptor, increasing insulin release when glucose is elevated, reducing glucagon secretion and slowing gastric emptying.
Formulations and schedules
Dulaglutide is supplied in a pre-filled subcutaneous injection device on a weekly schedule. Device design and strengths vary, so the patient leaflet is the correct source for product-specific use.
Useful information to track
- Weekly administration and injection site
- Blood-glucose readings requested by a clinician
- Digestive symptoms
- Supply and next prescription date
- Other diabetes medicines
Important safety considerations
- Nausea, diarrhoea and vomiting are among common effects
- Hypoglycaemia risk depends partly on other diabetes medicines
- Persistent abdominal pain requires medical assessment
- Dehydration and kidney problems can be relevant after severe gastrointestinal effects
- The medicine should not be shared or used outside the prescribed plan
Questions for a clinician or pharmacist
- How does dulaglutide fit with my other diabetes medicines?
- Which glucose readings should I record?
- Which side effects require a same-day call?
- How should a missed weekly administration be handled?
Authoritative references
Regulatory status, warnings and availability can change. Check the current official product information for your country.